NUS NU SKIN ENTERPRISES, INC.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1021561 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-15.3%
TTM net income YoY-313.7%
TTM EPS YoY-321.9%
Revenue 3-yr CAGR-12.9%
Net income 3-yr CAGR—
Margins
Gross margin67.8%
Operating margin-2.0%
Net margin-17.7%
FCF margin-2.0%
EBITDA margin1.8%
Returns
ROE-34.8%
ROA-18.6%
ROIC (approx.)-3.1%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity0.37x
Current ratio2.04x
Interest coverage-1.79x
Cash quality & payout
Operating cash flow / net income-0.06x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.49B | $1.73B | $1.97B | $2.23B | $2.70B |
| Cost of revenue | $453.76M | $550.23M | $611.85M | $630.91M | $675.22M |
| Gross profit | $1.03B | $1.18B | $1.36B | $1.59B | $2.02B |
| R&D expense | $10.80M | $13.00M | $22.60M | $23.30M | $27.20M |
| SG&A expense | $432.14M | $479.04M | $546.86M | $555.77M | $654.43M |
| Operating income | $65.76M | -$151.59M | $48.27M | $110.85M | $233.99M |
| Interest expense | $13.95M | $26.41M | $25.56M | $13.49M | $11.00M |
| Pretax income | $196.20M | -$175.05M | $26.58M | $88.97M | $232.46M |
| Income tax | $35.99M | -$28.46M | $17.98M | -$15.81M | $85.19M |
| Net income | $160.20M | -$146.59M | $8.60M | $104.78M | $147.27M |
| EBITDA | $118.02M | -$81.78M | $119.19M | $183.35M | $310.31M |
| EPS (basic) | 3.25 | -2.95 | 0.17 | 2.10 | 2.93 |
| EPS (diluted) | 3.18 | -2.95 | 0.17 | 2.07 | 2.86 |
| Weighted avg. shares (diluted) | 50.30M | 49.66M | 49.86M | 50.52M | 51.43M |
| Balance sheet | |||||
| Cash & equivalents | $238.63M | $186.88M | $256.06M | $264.73M | $339.59M |
| Short-term investments | $1.21M | $11.11M | $11.76M | $13.78M | $15.22M |
| Receivables | $39.54M | $50.78M | $58.70M | $47.36M | $41.30M |
| Inventory | $178.64M | $190.24M | $279.98M | $346.18M | $399.93M |
| Current assets | $547.70M | $538.60M | $701.87M | $759.87M | $872.95M |
| PP&E, net | $377.17M | $379.60M | $432.96M | $444.81M | $453.67M |
| Goodwill | $83.62M | $83.62M | $218.17M | $206.43M | $206.43M |
| Intangibles | $42.61M | $74.28M | $95.26M | $66.70M | $76.99M |
| Total assets | $1.41B | $1.47B | $1.81B | $1.82B | $1.91B |
| Current liabilities | $263.73M | $296.61M | $328.87M | $359.24M | $529.69M |
| Short-term debt | $20.00M | $30.00M | $25.00M | $25.00M | $107.50M |
| Long-term debt | $204.19M | $363.61M | $478.04M | $377.47M | $268.78M |
| Total debt | $224.19M | $393.61M | $503.04M | $402.47M | $376.28M |
| Total liabilities | $600.07M | $817.46M | $986.66M | $923.67M | $993.71M |
| Shareholders' equity | $805.24M | $651.46M | $821.97M | $897.30M | $912.77M |
| Net debt | -$14.44M | $206.73M | $246.98M | $137.74M | $36.69M |
| Cash flow statement | |||||
| Operating cash flow | $80.29M | $111.74M | $118.64M | $108.06M | $141.58M |
| Capital expenditure | $34.28M | $41.58M | $58.49M | $59.06M | $68.61M |
| Free cash flow | $46.01M | $70.16M | $60.15M | $49.01M | $72.97M |
| Investing cash flow | $170.66M | -$37.96M | -$134.50M | -$67.08M | -$88.73M |
| Financing cash flow | -$202.40M | -$133.18M | $10.73M | -$99.50M | -$104.70M |
| Depreciation & amortization | $52.26M | $69.81M | $70.92M | $72.51M | $76.32M |
| Stock-based compensation | $24.11M | $14.82M | $15.65M | $12.37M | $23.19M |
| Dividends paid | $11.83M | $11.93M | $77.62M | $77.02M | $76.27M |
| Share buybacks | $20.04M | $0 | $13.01M | $70.05M | $80.42M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.